1. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179
- Author
-
Bilal Anouti, Greg Andrew Durm, Sandra Althouse, and Nasser H. Hanna
- Subjects
Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Subset Analysis ,Cancer Research ,Prognostic variable ,Lung Neoplasms ,Paclitaxel ,Phases of clinical research ,Pemetrexed ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,Clinical Trials, Phase II as Topic ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Adjuvant therapy ,Humans ,Lung cancer ,Aged ,Etoposide ,Retrospective Studies ,Pneumonitis ,Univariate analysis ,business.industry ,Chemoradiotherapy ,Prognosis ,medicine.disease ,Consolidation Chemotherapy ,Survival Rate ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Cancer research ,Female ,Cisplatin ,business ,Follow-Up Studies - Abstract
The Hoosier Cancer Research Network (HCRN) LUN 14-179 is a phase II trial of consolidation pembrolizumab after concurrent chemoradiation for the treatment of patients with stage III non-small-cell lung cancer (NSCLC). Time to metastatic disease or death (TMDD), progression-free survival (PFS), and overall survival (OS) appear to be superior to that in historical controls of chemoradiation alone. Unfortunately, not all patients benefit from consolidation immunotherapy. We performed a univariate analysis to evaluate variables associated with PFS, metastatic disease, and OS.We conducted a retrospective analysis of patients enrolled in HCRN LUN 14-179. Data collected included age, sex, stage, smoking status, programmed death ligand 1 status, Grade (G) ≥ 2 versus G ≤ 1 adverse event, G ≤ 2 versus G ≥ 3 pneumonitis, duration of pembrolizumab (4 vs. ≥ 4 cycles), chemotherapy regimen, performance status 0 versus 1, time to start pembrolizumab (4-6 vs. 6-8 weeks from radiation), volume of lung receiving at least 20 Gy of radiation (VFrom April 2015 to December 2016, 93 patients were enrolled and 92 were included in the efficacy analysis (1 patient was ineligible). For TMDD, improved outcomes might be associated (P .1) with stage IIIA and ≥ 4 cycles of pembrolizumab. For PFS, improved outcomes (P .1) might be seen for ≥ 4 cycles of pembrolizumab, stage IIIA and VStage IIIA and longer duration of pembrolizumab treatment might be associated with prolonged TMDD, PFS, and OS for patients with stage III NSCLC treated with chemoradiation followed by pembrolizumab.
- Published
- 2020